18 results on '"Berling, Ingrid"'
Search Results
2. Proceedings of the Toxicology and Poisons Network Australasia (TAPNA) 2023 Annual Scientific Meeting: Perth, WA, Australia 26–28 April 2023.
- Author
-
Abouchedid, Rachelle, Hodgson, Sarah, Wong, Anselm, Berling, Ingrid, Brown, Jared, Toy, Brendan, Cairns, Rose, Ali, Zein, Noghrehchi, Firouzeh, Buckley, Nicholas, Raubenheimer, Jacques, Chitty, Kate, Dawson, Andrew, Isbister, Geoff, Chiew, Angela, Brett, Jonathan, Sullivan, Thomas, Bloom, Joshua, Chan, Gar, and Su, Mark
- Subjects
POISONING ,POISONS ,TOXICOLOGY ,SELF-poisoning ,ANNUAL meetings ,EARLY death - Published
- 2023
- Full Text
- View/download PDF
3. Environmental: Marine envenomations
- Author
-
Berling, Ingrid and Isbister, Geoffrey
- Published
- 2015
4. Extracorporeal treatment for ethylene glycol poisoning: systematic review and recommendations from the EXTRIP workgroup.
- Author
-
Ghannoum, Marc, Gosselin, Sophie, Hoffman, Robert S., Lavergne, Valery, Mégarbane, Bruno, Hassanian-Moghaddam, Hossein, Rif, Maria, Kallab, Siba, Bird, Steven, Wood, David M., Roberts, Darren M., for the EXTRIP Workgroup, Alhatali, Badria, Anseeuw, Kurt, Berling, Ingrid, Bouchard, Josée, Bunchman, Timothy E., Calello, Diane P., Chin, Paul K., and Doi, Kent
- Abstract
Ethylene glycol (EG) is metabolized into glycolate and oxalate and may cause metabolic acidemia, neurotoxicity, acute kidney injury (AKI), and death. Historically, treatment of EG toxicity included supportive care, correction of acid–base disturbances and antidotes (ethanol or fomepizole), and extracorporeal treatments (ECTRs), such as hemodialysis. With the wider availability of fomepizole, the indications for ECTRs in EG poisoning are debated. We conducted systematic reviews of the literature following published EXTRIP methods to determine the utility of ECTRs in the management of EG toxicity. The quality of the evidence and the strength of recommendations, either strong ("we recommend") or weak/conditional ("we suggest"), were graded according to the GRADE approach. A total of 226 articles met inclusion criteria. EG was assessed as dialyzable by intermittent hemodialysis (level of evidence = B) as was glycolate (Level of evidence = C). Clinical data were available for analysis on 446 patients, in whom overall mortality was 18.7%. In the subgroup of patients with a glycolate concentration ≤ 12 mmol/L (or anion gap ≤ 28 mmol/L), mortality was 3.6%; in this subgroup, outcomes in patients receiving ECTR were not better than in those who did not receive ECTR. The EXTRIP workgroup made the following recommendations for the use of ECTR in addition to supportive care over supportive care alone in the management of EG poisoning (very low quality of evidence for all recommendations): i) Suggest ECTR if fomepizole is used and EG concentration > 50 mmol/L OR osmol gap > 50; or ii) Recommend ECTR if ethanol is used and EG concentration > 50 mmol/L OR osmol gap > 50; or iii) Recommend ECTR if glycolate concentration is > 12 mmol/L or anion gap > 27 mmol/L; or iv) Suggest ECTR if glycolate concentration 8–12 mmol/L or anion gap 23–27 mmol/L; or v) Recommend ECTR if there are severe clinical features (coma, seizures, or AKI). In most settings, the workgroup recommends using intermittent hemodialysis over other ECTRs. If intermittent hemodialysis is not available, CKRT is recommended over other types of ECTR. Cessation of ECTR is recommended once the anion gap is < 18 mmol/L or suggested if EG concentration is < 4 mmol/L. The dosage of antidotes (fomepizole or ethanol) needs to be adjusted during ECTR. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning
- Author
-
Alhatali, Badria, Anseeuw, Kurt, Bird, Steven, Bouchard, Josée, Bunchman, Timothy E., Calello, Diane P., Chin, Paul K., Goldfarb, David S., Hassanian-Moghaddam, Hossein, Hoegberg, Lotte C., Kallab, Siba, Kebede, Sofia, Kielstein, Jan T., King, Joshua D., Li, Yi, Macedo, Etienne M., MacLaren, Rob, Megarbane, Bruno, Mowry, James B., Ostermann, Marlies E., Peng, Ai, Roy, Jean-Philippe, Shepherd, Greene, Vijayan, Anitha, Walsh, Steven J., Wong, Anselm, Wood, David M., Yates, Christopher, Ghannoum, Marc, Berling, Ingrid, Lavergne, Valéry, Roberts, Darren M., Galvao, Tais, Hoffman, Robert S., Nolin, Thomas D., Lewington, Andrew, Doi, Kent, and Gosselin, Sophie
- Published
- 2021
- Full Text
- View/download PDF
6. Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning
- Author
-
Ghannoum, Marc, primary, Berling, Ingrid, additional, Lavergne, Valéry, additional, Roberts, Darren M., additional, Galvao, Tais, additional, Hoffman, Robert S., additional, Nolin, Thomas D., additional, Lewington, Andrew, additional, Doi, Kent, additional, Gosselin, Sophie, additional, Alhatali, Badria, additional, Anseeuw, Kurt, additional, Bird, Steven, additional, Bouchard, Josée, additional, Bunchman, Timothy E., additional, Calello, Diane P., additional, Chin, Paul K., additional, Goldfarb, David S., additional, Hassanian-Moghaddam, Hossein, additional, Hoegberg, Lotte C., additional, Kallab, Siba, additional, Kebede, Sofia, additional, Kielstein, Jan T., additional, King, Joshua D., additional, Li, Yi, additional, Macedo, Etienne M., additional, MacLaren, Rob, additional, Megarbane, Bruno, additional, Mowry, James B., additional, Ostermann, Marlies E., additional, Peng, Ai, additional, Roy, Jean-Philippe, additional, Shepherd, Greene, additional, Vijayan, Anitha, additional, Walsh, Steven J., additional, Wong, Anselm, additional, Wood, David M., additional, and Yates, Christopher, additional
- Published
- 2021
- Full Text
- View/download PDF
7. The Half RR Rule: A Poor Rule of Thumb and Not a Risk Assessment Tool for QT Interval Prolongation
- Author
-
Berling, Ingrid, Isbister, Geoffrey K., and Heard, Kennon
- Published
- 2015
- Full Text
- View/download PDF
8. Endoscopic Treatment of Upper Gastrointestinal Obstruction After Ingestion of Illicit Drug Packets
- Author
-
Cowan, Timothy, Gibson, Robert, and Berling, Ingrid
- Published
- 2015
- Full Text
- View/download PDF
9. Extracorporeal treatment for calcium channel blocker poisoning: systematic review and recommendations from the EXTRIP workgroup
- Author
-
Wong, Anselm, Hoffman, Robert S., Walsh, Steven J., Roberts, Darren M., Gosselin, Sophie, Bunchman, Timothy E., Kebede, Sofia, Lavergne, Valery, Ghannoum, Marc, Badria Alhatali, Anseeuw, Kurt, Berling, Ingrid, Bouchard, Josee, Bird, Steven, Chin, Paul, Doi, Kent, Tais Galvao, Goldfarb, David, Hassanian, Hossein, Hoegberg, Lotte, Siba Kallab, Kielstein, Jan, Li, Yi, Macedo, Etienne, MacLaren, Rob, Megarbane, Bruno, Mowry, Jim, Nolin, Thomas D., Osterman, Marlies, Peng, Ai, Jean-Philippe Roy, Vijayan, Anitha, Wood, David, and Yates, Christopher
- Abstract
Calcium channel blockers (CCBs) are commonly used to treat conditions such as arterial hypertension and supraventricular dysrhythmias. Poisoning from these drugs can lead to severe morbidity and mortality. We aimed to determine the utility of extracorporeal treatments (ECTRs) in the management of CCB poisoning. We conducted systematic reviews of the literature, screened studies, extracted data, summarized findings, and formulated recommendations following published EXTRIP methods. A total of 83 publications (6 in vitro and 1 animal experiments, 55 case reports or case series, 19 pharmacokinetic studies, 1 cohort study and 1 systematic review) met inclusion criteria regarding the effect of ECTR. Toxicokinetic or pharmacokinetic data were available on 210 patients (including 32 for amlodipine, 20 for diltiazem, and 52 for verapamil). Regardless of the ECTR used, amlodipine, bepridil, diltiazem, felodipine, isradipine, mibefradil, nifedipine, nisoldipine, and verapamil were considered not dialyzable, with variable levels of evidence, while no dialyzability grading was possible for nicardipine and nitrendipine. Data were available for clinical analysis on 78 CCB poisoned patients (including 32 patients for amlodipine, 16 for diltiazem, and 23 for verapamil). Standard care (including high dose insulin euglycemic therapy) was not systematically administered. Clinical data did not suggest an improvement in outcomes with ECTR. Consequently, the EXTRIP workgroup recommends against using ECTR in addition to standard care for patients severely poisoned with either amlodipine, diltiazem or verapamil (strong recommendations, very low quality of the evidence (1D)). There were insufficient clinical data to draft recommendation for other CCBs, although the workgroup acknowledged the low dialyzability from, and lack of biological plausibility for, ECTR. Both dialyzability and clinical data do not support a clinical benefit from ECTRs for CCB poisoning. The EXTRIP workgroup recommends against using extracorporeal methods to enhance the elimination of amlodipine, diltiazem, and verapamil in patients with severe poisoning.
- Published
- 2021
- Full Text
- View/download PDF
10. Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup
- Author
-
Bouchard, Josée, Shepherd, Greene, Hoffman, Robert, Gosselin, Sophie, Roberts, Darren, Li, Yi, Nolin, Thomas, Lavergne, Valéry, Ghannoum, Marc, Alhatali, Badria, Anseeuw, Kurt, Bird, Steven, Berling, Ingrid, Bunchman, Timothy, Calello, Diane, Chin, Paul, Doi, Kent, Galvao, Tais, Goldfarb, David, Hassanian-Moghaddam, Hossein, Hoegberg, Lotte Cg, Kallab, Siba, Kebede, Sofia, Kielstein, Jan, Lewington, Andrew, Macedo, Etienne, Maclaren, Rob, Mégarbane, Bruno, Mowry, James, Ostermann, Marlies, Peng, Ai, Roy, Jean-Philippe, Vijayan, Anitha, Walsh, Steven, Wong, Anselm, Wood, David, Yates, Christopher, Mégarbane, Bruno, Service de Réanimation Médicale et Toxicologique [Hôpital Lariboisière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Optimisation thérapeutique en Neuropsychopharmacologie (OPTeN (UMR_S_1144 / U1144)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), and EXTRIP workgroup
- Subjects
Consensus ,Adrenergic beta-Antagonists ,Overdose ,030232 urology & nephrology ,Intoxication ,Critical Care and Intensive Care Medicine ,[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract ,03 medical and health sciences ,Beta-blockers ,Extracorporeal Membrane Oxygenation ,0302 clinical medicine ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Nadolol ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,medicine ,Humans ,030212 general & internal medicine ,Labetalol ,ECLS ,Practolol ,[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,Beta-adrenergic blocking agent ,RC86-88.9 ,business.industry ,Research ,Sotalol ,Medical emergencies. Critical care. Intensive care. First aid ,Atenolol ,Acebutolol ,[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Hemoperfusion ,[SDV.TOX] Life Sciences [q-bio]/Toxicology ,Bisoprolol ,Anesthesia ,Hemodialysis ,[SDV.TOX]Life Sciences [q-bio]/Toxicology ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,[SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract ,Drug Overdose ,business ,medicine.drug - Abstract
Backgroundβ-adrenergic antagonists (BAAs) are used to treat cardiovascular disease such as ischemic heart disease, congestive heart failure, dysrhythmias, and hypertension. Poisoning from BAAs can lead to severe morbidity and mortality. We aimed to determine the utility of extracorporeal treatments (ECTRs) in BAAs poisoning.MethodsWe conducted systematic reviews of the literature, screened studies, extracted data, and summarized findings following published EXTRIP methods.ResultsA total of 76 studies (4 in vitro and 2 animal experiments, 1 pharmacokinetic simulation study, 37 pharmacokinetic studies on patients with end-stage kidney disease, and 32 case reports or case series) met inclusion criteria. Toxicokinetic or pharmacokinetic data were available on 334 patients (including 73 for atenolol, 54 for propranolol, and 17 for sotalol). For intermittent hemodialysis, atenolol, nadolol, practolol, and sotalol were assessed as dialyzable; acebutolol, bisoprolol, and metipranolol were assessed as moderately dialyzable; metoprolol and talinolol were considered slightly dialyzable; and betaxolol, carvedilol, labetalol, mepindolol, propranolol, and timolol were considered not dialyzable. Data were available for clinical analysis on 37 BAA poisoned patients (including 9 patients for atenolol, 9 for propranolol, and 9 for sotalol), and no reliable comparison between the ECTR cohort and historical controls treated with standard care alone could be performed. The EXTRIP workgroup recommends against using ECTR for patients severely poisoned with propranolol (strong recommendation, very low quality evidence). The workgroup offered no recommendation for ECTR in patients severely poisoned with atenolol or sotalol because of apparent balance of risks and benefits, except for impaired kidney function in which ECTR is suggested (weak recommendation, very low quality of evidence). Indications for ECTR in patients with impaired kidney function include refractory bradycardia and hypotension for atenolol or sotalol poisoning, and recurrent torsade de pointes for sotalol. Although other BAAs were considered dialyzable, clinical data were too limited to develop recommendations.ConclusionsBAAs have different properties affecting their removal by ECTR. The EXTRIP workgroup assessed propranolol as non-dialyzable. Atenolol and sotalol were assessed as dialyzable in patients with kidney impairment, and the workgroup suggests ECTR in patients severely poisoned with these drugs when aforementioned indications are present.
- Published
- 2021
11. The antipsychotic story: changes in prescriptions and overdose without better safety
- Author
-
Berling, Ingrid, Nicholas Buckley, and Isbister, Geoffrey K.
- Subjects
Adult ,Male ,Pharmacoepidemiology ,Australia ,Length of Stay ,Middle Aged ,Hospitalization ,Young Adult ,Humans ,Female ,Prospective Studies ,Drug Overdose ,Practice Patterns, Physicians' ,Aged ,Antipsychotic Agents - Abstract
Morbidity and mortality from drug overdose has decreased over three decades. This is credited to safer drugs and therefore better outcomes in overdose. We aimed to investigate changing prescriptions of antipsychotic medications and associated changes in antipsychotic overdoses over a 26-year period.All antipsychotic poisoning presentations to a tertiary referral toxicology unit between 1987 and 2012 were reviewed. Data were collected prospectively on demographics, ingestion information, clinical effects, complications and treatment. Rates of antipsychotic drug use in Australia were obtained from Australian government publications for 1990-2011 and linked to overdose admissions by postcode.There were 3180 antipsychotic overdoses: 1235 first generation antipsychotics, 1695 'atypical' second generation antipsychotics and 250 lithium overdoses. Over 26 years, antipsychotic overdoses increased 1.8-fold, with first generation antipsychotics decreasing to one-fifth of their peak (≈80/year to 16) and second generation antipsychotics increasing to double this (≈160/year), olanzapine and quetiapine accounting for 78%. All antipsychotic overdoses had a median length of stay of 18.6 h, 15.7% admitted to intensive care unit, 10.4% ventilated and 0.13% died in hospital, which was the same for first generation compared to second generation antipsychotics. There was a 2.3-fold increase in antipsychotic prescriptions over the same period; first generation antipsychotics declined whereas there was a dramatic rise in second generation antipsychotics, mainly olanzapine, quetiapine and risperidone (79%).Over 26 years there was an increase in antipsychotic prescribing associated with an increase in antipsychotic overdoses. Although the type of antipsychotics changed, the morbidity and mortality remained the same, so that antipsychotics are an increasing proportion of overdose admissions.
- Published
- 2016
12. The antipsychotic story: changes in prescriptions and overdose without better safety
- Author
-
Berling, Ingrid, primary, Buckley, Nicholas A., additional, and Isbister, Geoffrey K., additional
- Published
- 2016
- Full Text
- View/download PDF
13. Marine envenomations.
- Author
-
Berling, Ingrid and Isbister, Geoffrey
- Published
- 2015
14. LETTERS.
- Author
-
Lobato-Berezo, Aejandro, Patterson, William, Anderson, L., Berling, Ingrid, and Isbister, Geoffrey
- Published
- 2015
15. Paracetamol in patents with pre-existing liver disease.
- Author
-
Clunas, Sally, Berling, Ingrid, Whyte, lan, and Coates, Penelope
- Published
- 2011
16. Warfarin poisoning with delayed rebound toxicity
- Author
-
Ahmed Mostafa, Ingrid Berling, Michael S. Roberts, Geoffrey K. Isbister, Jeffrey E. Grice, Berling, Ingrid, Mostafa, Ahmed, Grice, Jeffrey E, Roberts, Michael Stephen, and Isbister, Geoffrey K
- Subjects
Male ,Vitamin K ,Venlafaxine ,Acetylcysteine ,03 medical and health sciences ,0302 clinical medicine ,Pharmacokinetics ,Coagulopathy ,Ingestion ,Medicine ,Humans ,heterocyclic compounds ,030212 general & internal medicine ,International Normalized Ratio ,cardiovascular diseases ,vitamin K1 ,Acetaminophen ,business.industry ,Depression ,Warfarin ,Venlafaxine Hydrochloride ,Anticoagulants ,030208 emergency & critical care medicine ,Middle Aged ,medicine.disease ,poisoning ,warfarin ,Alcoholism ,Suicide ,Anesthesia ,Toxicity ,Emergency Medicine ,Drug Overdose ,overdose ,business ,Emergency Service, Hospital ,Warfarin overdose ,medicine.drug - Abstract
Background Intentional poisoning with warfarin is not the same as over-anticoagulation, for which guidelines exist. The coagulopathy resulting from a warfarin overdose is reversed with vitamin K 1 , the dose and timing of which is often guided by experience with the management of over-anticoagulation with warfarin therapy, rather than acute overdose. Case Report We report a case of a 50-year-old man who ingested an unknown amount of his warfarin, venlafaxine, and paracetamol. He presented with an international normalized ratio (INR) of 2.5, which steadily increased over 24 h to 7, despite receiving an initial 1 mg of vitamin K 1 . He was then treated with 5 mg vitamin K 1 , and once the INR returned to 4.5, 40 h post ingestion, he was discharged home. He was also treated with a full course of acetylcysteine for the paracetamol overdose. The following day his INR rebounded to 8.5 and he suffered a spontaneous epistaxis requiring readmission; he was treated with low titrated doses of vitamin K 1 . The warfarin concentration was 74.6 μg/mL 26 h post ingestion and decreased to 3.7 μg/mL over 72 h. Why Should an Emergency Physician Be Aware of This? Our case highlights the risk of a rebound elevated INR even 3 days after acute warfarin overdose despite treatment with vitamin K 1 . Understanding the pharmacokinetics of vitamin K 1 in comparison with warfarin, repeat INR testing, and continued treatment with oral vitamin K 1 may help avoid complications of rebound coagulopathy in warfarin overdose.
- Published
- 2017
17. 2-Methyl-4-chlorophenoxyacetic acid and bromoxynil herbicide death
- Author
-
Ahmed Mostafa, Geoffrey K. Isbister, Jeffrey E. Grice, Michael S. Roberts, Michael A. Downes, Nicholas A. Buckley, Gregory Medley, Ingrid Berling, Berling, Ingrid, Buckley, Nicholas A, Mostafa, Ahmed, Downes, Michael A, Grice, Jeffrey, Medley, Gregory, Roberts, Michael S, and Isbister, Geoffrey K
- Subjects
Adult ,Male ,Hyperthermia ,Time Factors ,Fever ,Overdose ,Poison control ,Oxidative phosphorylation ,2-Methyl-4-chlorophenoxyacetic Acid ,Pharmacology ,Toxicology ,MCPA ,Oxidative Phosphorylation ,chemistry.chemical_compound ,Fatal Outcome ,Nitriles ,medicine ,Humans ,Ingestion ,Hypoxia ,Bromoxynil ,Herbicides ,business.industry ,Poisoning ,Uncoupling agents ,General Medicine ,Carbon Dioxide ,medicine.disease ,Acute toxicity ,Heart Arrest ,Death ,chemistry ,Disease Progression ,business ,Analysis - Abstract
CASE REPORT: We report a fatal case of a 37 year old gentleman who ingested a MCPA/bromoxynil co-formulation herbicide. Although clinically well on initial examination, our patient declined dramatically over his 18 h admission with increasing CO2 production, hyperthermia and metabolic derangement to eventually die from cardiac asystole 20 h post ingestion. Two hours after ingestion the MCPA concentration was 83.9 μg/mL and bromoxynil concentration was 137 μg/mL. DISCUSSION: The patients' mechanism of death appeared to be uncoupling of oxidative phosphorylation, excess CO2 production and hyperthermia. There is limited knowledge on the acute toxicity of these herbicides, in particular bromoxynil, and this case highlights the relentless progression of severe toxicity in humans. The collaboration was supported by an NHMRC Program Grant (1055176). Geoff Isbister is supported by an NHMRC Senior Research Fellowship ID 1061041 and Mike Roberts is supported by an NHMRC Senior Principal Research Fellowship ID 1002611.
- Published
- 2015
18. Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.
- Author
-
Berling I, King JD, Shepherd G, Hoffman RS, Alhatali B, Lavergne V, Roberts DM, Gosselin S, Wilson G, Nolin TD, and Ghannoum M
- Subjects
- COVID-19, Chloroquine therapeutic use, Coronavirus Infections complications, Coronavirus Infections diagnosis, Coronavirus Infections epidemiology, Female, Humans, Hydroxychloroquine therapeutic use, Male, Outcome Assessment, Health Care, Pandemics statistics & numerical data, Pneumonia, Viral diagnosis, Pneumonia, Viral epidemiology, Poisoning therapy, Quinine therapeutic use, Renal Dialysis statistics & numerical data, Risk Assessment, United States, COVID-19 Drug Treatment, Chloroquine poisoning, Coronavirus Infections drug therapy, Hydroxychloroquine poisoning, Pneumonia, Viral drug therapy, Practice Guidelines as Topic, Quinine poisoning, Renal Dialysis methods
- Abstract
Background: Although chloroquine, hydroxychloroquine, and quinine are used for a range of medical conditions, recent research suggested a potential role in treating COVID-19. The resultant increase in prescribing was accompanied by an increase in adverse events, including severe toxicity and death. The Extracorporeal Treatments in Poisoning (EXTRIP) workgroup sought to determine the effect of and indications for extracorporeal treatments in cases of poisoning with these drugs., Methods: We conducted systematic reviews of the literature, screened studies, extracted data, and summarized findings following published EXTRIP methods., Results: A total of 44 studies (three in vitro studies, two animal studies, 28 patient reports or patient series, and 11 pharmacokinetic studies) met inclusion criteria regarding the effect of extracorporeal treatments. Toxicokinetic or pharmacokinetic analysis was available for 61 patients (13 chloroquine, three hydroxychloroquine, and 45 quinine). Clinical data were available for analysis from 38 patients, including 12 with chloroquine toxicity, one with hydroxychloroquine toxicity, and 25 with quinine toxicity. All three drugs were classified as non-dialyzable (not amenable to clinically significant removal by extracorporeal treatments). The available data do not support using extracorporeal treatments in addition to standard care for patients severely poisoned with either chloroquine or quinine (strong recommendation, very low quality of evidence). Although hydroxychloroquine was assessed as being non-dialyzable, the clinical evidence was not sufficient to support a formal recommendation regarding the use of extracorporeal treatments for this drug., Conclusions: On the basis of our systematic review and analysis, the EXTRIP workgroup recommends against using extracorporeal methods to enhance elimination of these drugs in patients with severe chloroquine or quinine poisoning., (Copyright © 2020 by the American Society of Nephrology.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.